Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: A longitudinal study

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1700-1706

  De Gruijl, Tanja D ^a   Bontkes, Hetty J ^a   Walboomers, Jan M M ^a   Stukart, Marij J ^a   Doekhie, Fania S ^a   Remmink, Ans J ^a   Helmerhorst, Theo J M ^a   Verheijen, René H M ^a   Duggan Keen, Margaret F ^b   Stern, Peter L ^b   Meijer, Chris J L M ^a   Scheper, Rik J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FOLLOW UP; HELPER CELL; HUMAN; LONGITUDINAL STUDY; PRIORITY JOURNAL; TUMOR IMMUNOLOGY; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; CARCINOMA; CELLS, CULTURED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PROSPECTIVE STUDIES; T-LYMPHOCYTES, HELPER-INDUCER; UTERINE CERVICAL NEOPLASMS;

EID: 0032522887     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. IARC. Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 64. The Human Papillomavirus. Lyon, France: IARC, 1995.
2. Frazer, I. H. Immunology of papillomavirus infection. Curr. Opin. Immunol., 8: 484-491, 1996.
3. Kadish, A. S., Romney, S. L., Ledwidge, R., Tindle, R., Fernando, G. J. P., Zee, S. Y., Van Ranst, M. A., and Burk, R. D. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J. Gen. Virol., 75: 2277-2284, 1994.
4. Luxton, J. C., Rowe, A. J., Cridland, J. C., Coletart, T., Wilson, P., and Shepherd, P. S. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J. Gen. Virol., 77: 1585-1593, 1996.
5. de Gruijl, T. D., Bontkes, H. J., Stukart, M. J., Walboomers, J. M. M., Remmink, A. J., Verheijen, R. H. M., Helmerhorst, T. J. M., Meijer, C. J. L. M., and Scheper, R. J. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral persistence. J. Gen. Virol., 77: 2183-2191, 1996.
6. Kadish, A. S., Ho, G. Y. F., Burk, R. D., Wang, Y., Romney, S. L., Ledwidge, R., and Angeletti, R. H. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst., 89: 1285-1293, 1997.
7. Tsukui, T., Hildesheim, A., Schiffman, M. H., Luci, J., III, Contois, D., Lawler, P., Rush, B. B., Lorincz, A. T., Corrigan, A., Burk, R. D., Qu, W., Marshall, M. A., Mann, D., Carrington, M., Clerici, M., Shearer, G. M., Carbone, D. P., Scott, D. R., Houghten, R. A., and Berzofsky, J. A. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. Cancer Res., 56: 3967-3974, 1996.
8. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, R. M. P., Hartman, M., Anholts, J. D. H., Schreuder, G. M. T., ter Harmsel, W. B., Fleuren, G. J., Trimbos, B. J., Kast, W. M., and Melief, C. J. M. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type-16 positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encode epitope. Cancer Res., 56: 582-588, 1996.
9. Remmink, A. J., Walboomers, J. M. M., Helmerhorst, T. J. M., Voorhorst, F. J., Rozendaal, L., Risse, E. K. J., Meijer, C. J. L. M., and Kenemans, P. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int. J. Cancer, 61: 306-311, 1995.
10. De Roda Husman, A. M., Walboomers, J. M. M., Meijer, C. J. L. M., Risse, E. K. J., Schipper, M. E. I., Helmerhorst, T. J. M., Bleker, O. P., Van den Brule, A. J. C., and Snijders, P. J. F. Analysis of cytomorphologically abnormal cervical scrapes for the presence of 27 mucosotropic human papillomavirus genotypes using polymerase chain reaction. Int. J. Cancer, 56: 802-806, 1994.
11. De Roda Husman, A. M., Walboomers, J. M. M., Van den Brule, A. J. C., Meijer, C. J. L. M., and Snijders, P. J. F. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J. Gen. Virol., 76: 1057-1062, 1995.
12. Jacobs, M. V., De Roda Husman, A. M., Van den Brule, A. J. C., Snijders, P. J. F., Meijer, C. J. L. M., and Walboomers, J. M. M. Group specific differentiation between high and low risk human papillomavirus genotypes by using the general primer (GP5+/6+) mediated PCR and two cocktails of oligoprobes. J. Clin. Microbiol., 33: 901-905, 1995.
13. Duggan-Keen, M. F., Keating, P. J., Stevens, F. R. A., Sinnott, P., Snijders, P. J. F., Walboomers, J. M. M., Davidson, S., Hunter, R. D., Dyer, P. A., and Stern, P. L. Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. Eur. J. Immunogenet., 23: 275-284, 1996.
14. Ertl, H. C. J., Dietzschold, B., Gore, M., Otvos, L., Larson, J. K., Wunner, W. H., and Koprowski, H. Induction of rabies virus-specific T-helper cells by synthetic peptides that carry dominant T-helper cell epitopes of the viral ribonucleoprotein. J. Virol., 63: 2885-2892, 1989.
15. Zinkemagel, R. M. Immunology taught by viruses. Science (Washington DC), 271: 173-178, 1996.
16. de Gruijl, T. D., Bontkes, H. J., Walboomers, J. M. M., Stukart, M. J., Robbesom, A. A. J. P., von Blomberg-van der Flier, B. M. E., Herbrink, P., Remmink, A. J., Verheijen, R. H. M., Helmerhorst, T. J. M., Meijer, C. J. L. M., and Scheper, R. J. Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int. J. Cancer. 68: 731-738, 1996.
17. Stoler, M. H., Rhodes, C. R., Whitbeck, A., Wolinsky, S. M., Chow, L. T., and Broker, T. R. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum. Pathol., 23: 117-128, 1992.
18. Bohm, S., Wilczynski, S. P., Pfister, H., and Iftner, T. The predominant messenger RNA class in HPV16-infected genital neoplasias does not encode the E6 or the E7 protein. Int. J. Cancer, 55: 791-798, 1993.
19. Dürst, M., Glitz, D., Schneider, A., and Zur Hausen, H. Human papillomavirus type 16 (HPV16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology, 189: 132-140, 1992.
20. Chambers, M. A., Wei, Z., Coleman, N., Nash, A. A., and Stanley, M. A. Natural presentation of human papillomavirus type-16 E7 protein to immunocompetent mice results in antigen-specific sensitization or sustained unresponsiveness. Eur. J. Immunol., 24: 738-745, 1994.
21. Apple, R. J., Becker, T. M., Wheeler, C. M., and Erlich, H. A. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst., 87: 427-436, 1995.
22. Apple, R. J., Erlich, H. A., Klitz, W., Manos, M. M., Becker, T. M., and Wheeler, C. M. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nat. Genet., 6: 157-162, 1994.
23. Wank, R., Schendel, D. J., and Thomssen, C. HLA antigens and cervical carcinoma. Nature (Lond.), 356: 22-23, 1992.
24. Altmann, A., Jochmus-Kudielka, J., Frank, R., Gausepohl, H., Moebius, U., Gissmann, L., and Meuer, S. C. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur. J. Cancer, 28: 326-333, 1992.
25. Tindle, R. W. Human papillomavirus vaccines for cervical cancer. Curr. Opin. Immunol., 8: 643-650, 1996.
26. Borysiewicz, L. K., Fiander, A., Nimako, M., Man, S., Wilkinson, G. W. G., Westmoreland, D., Evans, S. A., Adams, M., Stacey, S. N., Boursnell, M. E. G., Rutherford, E., Hickling, J. K., and Inglis, S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet, 347: 1523-1527, 1996.
27. Lin, K-Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., and Wu, T-C. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res., 56: 21-26, 1996.
28. Wu, T-C., Guarnieri, F. G., Staveley-O'Carroll, K. F., Viscidi, R. P., Levitsky, H., Hedrick, L., Cho, K. R., August, J. T., and Pardoll, D. M. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc. Natl. Acad. Sci. USA, 92: 11671-11675, 1995.
29. Majewski, S., Malejczyk, J., and Jablonska, S. The role of cytokines and other factors in HPV infection and HPV-associated tumors. Papillomavirus Report, 7: 143-154, 1996.
30. Cromme, F. V., Meijer, C. J. L. M., Snijders, P. J. F., Uyterlinde, A., Kenemans, P., Helmerhorst, T., Stern, P. L., Van den Brule, A. J. C., and Walboomers, J. M. M. Analysis of MHC class I and II expression in relation to presence of HPV genotype in premalignant and malignant cervical lesions. Br. J. Cancer, 68: 1372-1380, 1993.
31. Bartholomew, J. S., Glenville, S., Sarkar, S., Burt, D. J., Stanley, M. A., Ruiz-Cabello, F., Chengang, J., Garrido, F., and Stern, P. L. Integration of high-risk human papillomavirus DNA is linked to the down-regulation of human leukocyte antigen class I antigens by steroid hormones in cervical tumor cells. Cancer Res., 57: 937-942, 1997.
32. Kono, K., Ressing, M. E., Brandt, R. M. P., Melief, C. J. M., Potkul, R. K., Andersson, B., Petersson, M., Kast, W. M., and Kiessling, R. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res., 2: 1825-1828, 1996.